PT - JOURNAL ARTICLE AU - Ewa Bandurska AU - Iwona Damps-Konstanska AU - Piotr Popowski AU - Taduesz Jedrzejczyk AU - Piotr Janowiak AU - Katarzyna Swietnicka AU - Ewa Jassem TI - Economic effectiveness of integrated care model (ICM) for patients with severe chronic obstructive pulmonary disease (COPD) AID - 10.1183/13993003.congress-2015.PA1589 DP - 2015 Sep 01 TA - European Respiratory Journal PG - PA1589 VI - 46 IP - suppl 59 4099 - http://erj.ersjournals.com/content/46/suppl_59/PA1589.short 4100 - http://erj.ersjournals.com/content/46/suppl_59/PA1589.full SO - Eur Respir J2015 Sep 01; 46 AB - Introduction: ICM in COPD patients had been earlier proven to provide clinical benefits, manifested mainly by better compliance and milder course of disease. This study was designed to assess the economic effects of ICM in patients with severe COPD.Methods: Within a pilot project conducted between 2011 and 2014, 41 severe COPD patients were subjected to ICM including home support, to decrease the frequency of disease events and improve quality of life. Using the National Health Fund data, medical expenditures in these patients were compared in two consecutive 6-month periods: before and after implementing ICM.Results: After implementing ICM the average 6-month general costs decreased from 5627 PLN (1349 EUR) to 3576 PLN (856 EUR), COPD related costs from 3191 PLN (765 EUR) to 1741 PLN (418 EUR), and exacerbation-related costs from 2444 PLN (586 EUR) to 735 PLN (176 EUR). All cost benefit indicators confirmed high economic efficacy of ICM View this table:Results of CBA analysisConclusions: ICM decreases the costs of care in severe COPD patients, mainly by preventing exacerbations.ICM was financed by grant from Novartis and City Council of Gdansk.